ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1620

Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry

Pablo Mesa-del-Castillo B.1, Ines Yago Ugarte1, jose Miguel Bolarin2, Berta Lopez Montesinos3, Honorio Barranco Gonzalez3, Daniel Clemente4, Isabel Valls Ferran4, Juan Carlos Lopez Robledillo4, Beatriz Bravo5, Marina Rubio Prats5, Carmen Alba Linero6, Laura Martin Pedraz6, Esmeralda Nuñez Cuadros6, Maria Concepción Mir Perelló7, Noelia Druetta7, Mari Carmen Pinedo Gago8, Alex Fonollosa Calduch8, Alex Souto9, Fernando Lopez Lopez10, Cristina Zarallo Reales11, Maria Jerez Fidalgo11, Jorge Solana Fajardo11, NATALIA PALMOU FONTANA12, Rosalía Demetrio-Pablo13, Maria Vega Jovani Casano14, Jose Juan Mondejar Garcia15, Anahy Maria Brandy-Garcia16, Alba Garcia Lopez17, Belen Sevilla18, Jose Luis Garcia Serrano19, Alfredo Tagarro20, Mar Esteban20, Joan Calzada21, Jesus Diaz Carrascosa21, Cesar Gavilan Martin22, Encarna Mengual Verdu22, Ester Carreño Salas23, Sheila Recuero Diaz23, Neus Quilis Marti24, Mari Carmen Alvarado Valero25, José Rosas26, Juan Luis Sanchez Sevilla27, Juan Carlos Nieto28, Lucia Ibares28, Jaime De Inocencio29, Pilar Tejada29 and Almudena Roman Pascual30, 1Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 2CENTIC (Centro tecnológico de las TICs de Murcia), Murcia, Spain, 3Hospital Universitari i Politècnic La Fe, Valencia, Spain, 4Hospital Infantil Universitario Niño Jesús, Madrid, Spain, 5Hospital Universitario Virgen de las Nieves, Granada, Spain, 6Hospital Universitario Regional de Málaga, Malaga, Spain, 7Hospital Universitari Son Espases, Palma de Mallorca, Spain, 8Hospital Universitario de Cruces, Bilbao, Spain, 9Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, 10Hospital Clínico Universitario de Santiago, Santiago de Compostela, South Georgia & South Sandwich Islands, 11Hospital Universitario de Badajoz, Badajoz, Spain, 12UNIVERSITARY HOSPITAL MARQUES VALDECILLA, Santander, Spain, 13Hospital Universitario de Marqués de Valdecilla, Santander, Spain, 14National Health system, Alicante, Spain, 15Hospital General Universitario de Alicante, Alicante, Spain, 16Hospital Germans Trias i Pujol, Badalona, Spain, 17Hospital Universitario de Cabueñes, Gijón, Spain, 18Division of Paediatrics, Hospital Universitario San Cecilio, Granada, Spain, 19Hospital Universitario Clínico San Cecilio, Granada, 20Hospital Universitario Infanta Sofía, Madrid, Spain, 21Hospital maternoinfantil Sant Joan de Déu, Barcelona, Spain, 22Hospital Universitario San Juan de Alicante, Alicante, Spain, 23Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 24Hospital del Vinalopó, Elche, Spain, 25Hospital del Vinalopó, Elche, 26Hospital Marina Baixa, Villajoyosa, 27Hospital Marina Baixa, Villajoyosa, Spain, 28Hospital General Universitario Gregorio Marañón, Madrid, Spain, 29Hospital Universitario 12 de Octubre, Madrid, Spain, 30Hospital Universitario Rey Juan Carlos, Madrid, Spain

Meeting: ACR Convergence 2021

Keywords: Eye Disorders, Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Pediatric noninfectious uveitis is a major clinical challenge for Pediatric ophthalmologists and rheumatologists. The burden of disease is considerable and etiological diagnosis elusive in many cases. Uveitis outcomes have improved dramatically with antirheumatic drugs, especially anti TNFα agents.

Methods: A multicenter cross sectional and retrospective cohort study was conducted from october 2019 to march 2021. Multidisciplinary participation was mandatory for joining the study; to ensure homogeneity data of associated systemic disease and disease modifying antirheumatic drug (DMARD) therapy were provided by rheumatologist and ophthalmology related data were introduced by ophthalmologist, in a web based form. Only patients with uveitis onset before 16th birthday and complete data were included in the analysis. Three distinct groups were made for comparison: Juvenile Idiopathic Arthritis related uveitis (JIAu), Idiopathic childhood uveitis (ICU) and Pars Planitis (PP).

Results: A total of 501 patients from 22 centers were included in the analysis, 310 (61.9 %) with an associated immune disease, 91 (18.2%) with an ophthalmologically distinguishable uveitis and 100 (20%) idiopathic. JIAu accounted for 54.8 % (275), 259 (51.6%) non B27 related; 67 patients (13.3%) had PP. JIAu was significantly associated with female gender, younger age at uveitis onset, ANA positive, anterior location and insidious presentation, with less ocular complications, systemic corticoid use and ocular surgeries. DMARD exposure was more prolonged, started earlier after uveitis onset and had less unilateral severe visual loss. ICU tended to present as panuveitis and was associated with male gender, older age at onset, ANA negative, acute presentation and acute clinical course. Ocular complications were higher, mainly synechiae at onset and cataracts. Exposure to DMARD was significantly lower for both synthetic and biologic agents. PP showed the highest complication rate within groups (71.6%), especially cataracts during follow up and greater tendency to present vitreoretinal complications (macular edema, epiretinal membrane and retinoschisis), requiring ocular surgery more frequently. PP patients also received more systemic steroids, showing no difference in regards to DMARD use.

Conclusion: We present a large cohort of childhood onset not infectious uveitis. Homogeneity of data was cared for with a multidisciplinary approach, but case selection bias may have occurred as participation and case selection was voluntary. Our data suggest that differences in outcome may correspond partially to differences in treatment approach depending on the aetiology or diagnosis associated with the ocular inflammatory disease. Surprisingly, JIAu patients showed the best prognosis despite its chronicity in comparison with the other groups, traditionally considered mild self-limited diseases. Awareness of ophthalmologists and rheumatologists on these observations could ameliorate the burden of disease by inducing rheumatology referral for early treatment.

Table 1. Demographic and clinical data.

Table 2. Ocular complications, surgery and poor visual outcome.

Table 3. Treatment.


Disclosures: P. Mesa-del-Castillo B., Pfizer, 6, Abvvie, 6; I. Yago Ugarte, None; j. Bolarin, None; B. Lopez Montesinos, None; H. Barranco Gonzalez, None; D. Clemente, Pfizer, 6, Roche, 6, Lilly, 5, Sanofi, 5; I. Valls Ferran, None; J. Lopez Robledillo, None; B. Bravo, None; M. Rubio Prats, None; C. Alba Linero, None; L. Martin Pedraz, None; E. Nuñez Cuadros, None; M. Mir Perelló, None; N. Druetta, None; M. Pinedo Gago, None; A. Fonollosa Calduch, None; A. Souto, None; F. Lopez Lopez, Essilor España, 7, Sociedad Española Inflamación Ocular, 6; C. Zarallo Reales, None; M. Jerez Fidalgo, None; J. Solana Fajardo, None; N. PALMOU FONTANA, Novartis, 5, GSK, 6, Amgen, 6, Sanofi, 6; R. Demetrio-Pablo, None; M. Jovani Casano, None; J. Mondejar Garcia, None; A. Brandy-Garcia, None; A. Garcia Lopez, None; B. Sevilla, None; J. Garcia Serrano, None; A. Tagarro, None; M. Esteban, None; J. Calzada, None; J. Diaz Carrascosa, None; C. Gavilan Martin, None; E. Mengual Verdu, None; E. Carreño Salas, Abbvie, 6, Brill, 6, Eyevensis, 1, Allimera, 2; S. Recuero Diaz, None; N. Quilis Marti, None; M. Alvarado Valero, None; J. Rosas, None; J. Sanchez Sevilla, None; J. Nieto, None; L. Ibares, None; J. De Inocencio, None; P. Tejada, None; A. Roman Pascual, None.

To cite this abstract in AMA style:

Mesa-del-Castillo B. P, Yago Ugarte I, Bolarin j, Lopez Montesinos B, Barranco Gonzalez H, Clemente D, Valls Ferran I, Lopez Robledillo J, Bravo B, Rubio Prats M, Alba Linero C, Martin Pedraz L, Nuñez Cuadros E, Mir Perelló M, Druetta N, Pinedo Gago M, Fonollosa Calduch A, Souto A, Lopez Lopez F, Zarallo Reales C, Jerez Fidalgo M, Solana Fajardo J, PALMOU FONTANA N, Demetrio-Pablo R, Jovani Casano M, Mondejar Garcia J, Brandy-Garcia A, Garcia Lopez A, Sevilla B, Garcia Serrano J, Tagarro A, Esteban M, Calzada J, Diaz Carrascosa J, Gavilan Martin C, Mengual Verdu E, Carreño Salas E, Recuero Diaz S, Quilis Marti N, Alvarado Valero M, Rosas J, Sanchez Sevilla J, Nieto J, Ibares L, De Inocencio J, Tejada P, Roman Pascual A. Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/pediatric-onset-16-years-non-infectious-uveitis-results-from-spanish-national-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pediatric-onset-16-years-non-infectious-uveitis-results-from-spanish-national-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology